Industrial innovation churns out increasingly unnatural products and technologies amid scientific uncertainty about their harmful effects. We argue that a quick regulatory response to the discovery that certain innovations are harmful is an important indicator for evaluating the performance of...

Funding agencies and large public scientific institutions are increasingly using the term “research portfolio” as a means of characterising their research. While portfolios have long been used as a heuristic for managing corporate R&D (i.e., R&D aimed at gaining tangible economic benefits),...

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D...